(NASDAQ: BMEA) Biomea Fusion's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 90.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.86%.
Biomea Fusion's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast BMEA's revenue for 2026 to be $892,627,770, with the lowest BMEA revenue forecast at $892,627,770, and the highest BMEA revenue forecast at $892,627,770. On average, 1 Wall Street analysts forecast BMEA's revenue for 2027 to be $332,712,124, with the lowest BMEA revenue forecast at $332,712,124, and the highest BMEA revenue forecast at $332,712,124.
In 2028, BMEA is forecast to generate $2,082,798,130 in revenue, with the lowest revenue forecast at $2,082,798,130 and the highest revenue forecast at $2,082,798,130.